← Leaderboards
Jose Maria Martinez-Navio
University Of Miami School Of Medicine
$2,417,661
Attributed
$2,417,661
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,417,661 · 3
By mechanism
R01$1,548,010 · 1
R21$869,651 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Camillo Ricordi$25,964,244
- Lawrence H Boise$10,842,636
- Derek Michael Dykxhoorn$5,902,943
- Mariano Juan Kanamori Nishimura$10,512,795
- Emily Mellissa Cherenack$210,690
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyHiv AntibodiesProphylacticRecombinant Adeno-Associated Virus (Raav)MonkeysTransgene ExpressionExperimental StudyNeutralizing AntibodyInjectionsProphylactic TreatmentHiv InfectionsImmune SystemMediatingMacacaAntibodiesClinical TrialsAdeno-Associated Viral VectorIn VivoGene DeliveryCost EfficiencyFutureBypassImmunoglobulin GImmunogenicity
Grant awards (7)
Overcoming preexisting antibodies to recombinant AAV vectors in rhesus macaques$187,254
R21 · FY2025 · AI · contact PI
Vectored delivery of anti-HIV antibodies for mucosal protection$1
R01 · FY2025 · AI · contact PI
Vectored delivery of anti-HIV antibodies for mucosal protection$762,712
R01 · FY2024 · AI · contact PI
Overcoming preexisting antibodies to recombinant AAV vectors in rhesus macaques$244,795
R21 · FY2024 · AI · contact PI
Vectored delivery of anti-HIV antibodies for mucosal protection$785,297
R01 · FY2023 · AI · contact PI
A tolerogenic approach for the long-term delivery of antibodies with AAV$231,775
R21 · FY2021 · AI · contact PI
A tolerogenic approach for the long-term delivery of antibodies with AAV$205,827
R21 · FY2020 · AI · contact PI